Portal de Periódicos da CAPES

Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer

2020; Lippincott Williams & Wilkins; Volume: 205; Issue: 2 Linguagem: Inglês

10.1097/ju.0000000000001402

1527-3792

Juan Moróte, Imma Comas,

Prostate Cancer Diagnosis and Treatment

No AccessJournal of UrologyLetters to the Editor1 Feb 2021Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerF. Saad, N. Fleshner, T. Pickles, T. Niazi, H. Lukka, F. Pouliot, I. Martins and L. Klotzis a letter which has replyReply by Authors Juan Morote, and Imma Comas Juan MoroteJuan Morote *Correspondence: Department of Urology and Urology Research Unit, Vall dHebron Hospital and Research Institute, Universitat E-mail Address: [email protected]; telephone: +34629011936 Department of Urology and Urology Research Unit, Vall d´Hebron Hospital and Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain More articles by this author , and Imma ComasImma Comas Department of Biochemistry, Vall d´Hebron Hospital, Barcelona, Spain More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001402AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail References 1. : Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: a systematic review. Actas Urol Esp 2016; 40: 477. Google Scholar 2. : Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405. Google Scholar 3. : Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy. Int J Urol 2016; 23: 957. Google Scholar 4. : Serum testosterone levels in prostate cancer patients undergoing luteinizing hormone-releasing hormone agonist therapy. Clin Genitourin Cancer 2017; 16: e491. Google Scholar 5. : Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients. J Biomed Sci 2017; 24: 81. Google Scholar 6. : Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017.http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration. Eur Urol 2018; 73: e134. Google Scholar 7. : Serum luteinizing hormone testing can identify optimal medical castration. Eur Urol Open Sci 2020; 19: 24. Google Scholar © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsRelated articlesJournal of UrologyOct 7, 2020, 12:00:00 AMReply by Authors Volume 205Issue 2February 2021Page: 343-345 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Juan Morote Department of Urology and Urology Research Unit, Vall d´Hebron Hospital and Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain *Correspondence: Department of Urology and Urology Research Unit, Vall dHebron Hospital and Research Institute, Universitat E-mail Address: [email protected]; telephone: +34629011936 More articles by this author Imma Comas Department of Biochemistry, Vall d´Hebron Hospital, Barcelona, Spain More articles by this author Expand All Advertisement PDF DownloadLoading ...